Trial Profile
Long Term Documentation of the Safety and Efficacy as Well as the Effects on Work Productivity in Patients With Moderate to Severe Plaque Psoriasis Treated With HUMIRA (Adalimumab) in Routine Clinical Practice (LOTOS)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Jul 2019
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Therapeutic Use
- Acronyms LOTOS
- Sponsors Abbott Laboratories; AbbVie
- 03 Jul 2019 Status changed from active, no longer recruiting to completed.
- 29 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 09 Feb 2018 Planned End Date changed from 15 Oct 2018 to 31 Oct 2020.